Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | IDH2 | P48735 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526669 | 0.83 | KMT2A (0.60) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7524044 | 0.82 | KIF11 (0.40) | KIF11AKR1C3DHODHMAPT | |
| SCHEMBL7515459 | 0.78 | IDO1 (0.43) | RAPGEF4ALDH1A1GAA | |
| SCHEMBL15913218 | 0.77 | KIF11 (0.53) | KIF11AKR1C3AKR1C2ADORA2AIDH2 | |
| SCHEMBL7517596 | 0.76 | ALDH1A1 (0.54) | ALDH1A1MAPTRAB9ASMN1; SMN2HTT | |
| SCHEMBL7528061 | 0.74 | KIF11 (0.52) | KIF11AKR1C3AKR1C2ADORA2AIDH2 | |
| SCHEMBL15992074 | 0.74 | KIF11 (0.52) | KIF11ADORA2AIDH2DHODHRAPGEF4 | |
| SCHEMBL7559638 | 0.74 | KIF11 (0.53) | KIF11ADORA2AIDH2DHODHRAPGEF4 | |
| SCHEMBL394991 | 0.74 | KIF11 (0.70) | KIF11AKR1C3AKR1C2ADORA2AIDH2 | |
| SCHEMBL17477726 | 0.72 | KIF11 (0.50) | KIF11AKR1C3AKR1C2ADORA2AIDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350173-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3350173-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| EP-3350173-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| EP-1173420-A2 | HETEROCYCLIC COMPOUNDS HAVING ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000053581-A2 | HETEROCYCLIC COMPOUNDS HAVING ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189776-B2 | Stereoselective process | CYP4A11, CYP4B1, CYP3A4 | KIF11 1740/4885AKR1C3 54/4885AKR1C2 71/4885 |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | CYP4A11, CYP4B1, CYP3A4 | KIF11 1740/4885AKR1C3 54/4885AKR1C2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.